Terramycin Ophthalmic Ointment w/ Polymyxin B Sulfate - $9.40
3.5 grams (1/8 oz.)
Manufactured by Pfizer Animal Health, Istanbul, Turkey
Expiration: JULY 2021
Expiration: JULY 2021
No Telephone Orders. All orders must go through PayPal. No exceptions.
International Orders, must contact us, PRIOR to placing an order.
International Orders, must contact us, PRIOR to placing an order.
Ships USPS First Class® with tracking. USPS Priority® shipping options available during checkout.
Brand Name: Terramycin Ophthalmic Ointment with Polymyxin B Sulfate
Manufactured by: Pfizer Animal Health, Istanbul, Turkey
Generic Name: Oxytetracycline HCl, Polymyxin B sulfate
For: Cats, Dogs, Reptiles, Birds and Companion Pets
Package Size: 3.5 grams (1/8 oz.)
Application: Animal Eye Care
Manufactured by: Pfizer Animal Health, Istanbul, Turkey
Generic Name: Oxytetracycline HCl, Polymyxin B sulfate
For: Cats, Dogs, Reptiles, Birds and Companion Pets
Package Size: 3.5 grams (1/8 oz.)
Application: Animal Eye Care
Terramycin Ophthalmic Ointment w/ Polymyxin B Sulfate - White Boxed
$10.50 - 3.5 grams (1/8 oz.)
$10.50 - 3.5 grams (1/8 oz.)
Manufactured by PT. Pfizer Indonesia, Jakarta, Indonesia
Expiration: August 2023
Expiration: August 2023
Brand Name: Terramycin Ophthalmic Ointment with Polymyxin B Sulfate
Manufactured by: PT. Pfizer Indonesia, Jakarta, Indonesia
Generic Name: Oxytetracycline HCl, Polymyxin B sulfate
Package Size: 3.5 grams (1/8 oz.)
Application: Animal Eye Care
Manufactured by: PT. Pfizer Indonesia, Jakarta, Indonesia
Generic Name: Oxytetracycline HCl, Polymyxin B sulfate
Package Size: 3.5 grams (1/8 oz.)
Application: Animal Eye Care
________________________________________________________________________________
FDA NADA Number: 008-763
Sponsor: Pfizer Animal Health, Istanbul, Turkey
Ingredients: Oxytetracycline Hydrochloride, Polymyxin B Sulfate
Species: CATS (DOMESTIC) (Cat, no use class stated or implied)
DOGS (Dog, no use class stated or implied)
Routes of Administration: Opthalmological
Dosage Form: Ointment
Dispensing Status: OTC
Dosage Amount, Indications & Limitations: 524.1662b Oxytetracycline hydrochloride, polymyxin B sulfate ophthalmic ointment.
Specifications: Each gram of the ointment contains oxytetracycline hydrochloride equivalent to 5 milligrams of oxytetracycline and 10,000 units of polymyxin B sulfate.
Conditions of use:
Dogs
Amount: It is administered topically to the eye two to four times daily.
Indications: The drug is used for the prophylaxis and local treatment of superficial ocular infections due to oxytetracycline- and polymyxin-sensitive organisms. These infections include the following: Ocular infections due to streptococci, rickettsiae E. coli, and A. aerogenes (such as conjunctivitis, keratitis, pinkeye, corneal ulcer, and blepharitis in dogs); ocular infections due to secondary bacterial complications associated with distemper in dogs; and ocular infections due to bacterial inflammatory conditions which may occur secondary to other diseases in dogs.
Limitations: Allergic reactions may occasionally occur. Treatment should be discontinued if reactions are severe. If new infections due to nonsensitive bacteria or fungi appear during therapy, appropriate measures should be taken.
Cats
Amount: It is administered topically to the eye two to four times daily.
Indications: The drug is used for the prophylaxis and local treatment of superficial ocular infections due to oxytetracycline- and polymyxin-sensitive organisms. These infections include the following: Ocular infections due to streptococci, rickettsiae E. coli, and A. aerogenes (such as conjunctivitis, keratitis, pinkeye, corneal ulcer, and blepharitis in cats) and ocular infections due to bacterial inflammatory conditions which may occur secondary to other diseases in cats.
Limitations: Allergic reactions may occasionally occur. Treatment should be discontinued if reactions are severe. If new infections due to nonsensitive bacteria or fungi appear during therapy, appropriate measures should be taken.
Ingredients: Oxytetracycline Hydrochloride, Polymyxin B Sulfate
Species: CATS (DOMESTIC) (Cat, no use class stated or implied)
DOGS (Dog, no use class stated or implied)
Routes of Administration: Opthalmological
Dosage Form: Ointment
Dispensing Status: OTC
Dosage Amount, Indications & Limitations: 524.1662b Oxytetracycline hydrochloride, polymyxin B sulfate ophthalmic ointment.
Specifications: Each gram of the ointment contains oxytetracycline hydrochloride equivalent to 5 milligrams of oxytetracycline and 10,000 units of polymyxin B sulfate.
Conditions of use:
Dogs
Amount: It is administered topically to the eye two to four times daily.
Indications: The drug is used for the prophylaxis and local treatment of superficial ocular infections due to oxytetracycline- and polymyxin-sensitive organisms. These infections include the following: Ocular infections due to streptococci, rickettsiae E. coli, and A. aerogenes (such as conjunctivitis, keratitis, pinkeye, corneal ulcer, and blepharitis in dogs); ocular infections due to secondary bacterial complications associated with distemper in dogs; and ocular infections due to bacterial inflammatory conditions which may occur secondary to other diseases in dogs.
Limitations: Allergic reactions may occasionally occur. Treatment should be discontinued if reactions are severe. If new infections due to nonsensitive bacteria or fungi appear during therapy, appropriate measures should be taken.
Cats
Amount: It is administered topically to the eye two to four times daily.
Indications: The drug is used for the prophylaxis and local treatment of superficial ocular infections due to oxytetracycline- and polymyxin-sensitive organisms. These infections include the following: Ocular infections due to streptococci, rickettsiae E. coli, and A. aerogenes (such as conjunctivitis, keratitis, pinkeye, corneal ulcer, and blepharitis in cats) and ocular infections due to bacterial inflammatory conditions which may occur secondary to other diseases in cats.
Limitations: Allergic reactions may occasionally occur. Treatment should be discontinued if reactions are severe. If new infections due to nonsensitive bacteria or fungi appear during therapy, appropriate measures should be taken.
